Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Palma, 2014, The oligometastatic state - separating truth from wishful thinking, Nat Rev Clin Oncol, 11, 549, 10.1038/nrclinonc.2014.96 Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0 Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Iyengar, 2018, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial, JAMA Oncol, 4, e173501, 10.1001/jamaoncol.2017.3501 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek, Cornelis, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. 2020. doi:10. Chalkidou, 2021, Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study, Lancet Oncol, 22, 98, 10.1016/S1470-2045(20)30537-4 Schanne, 2019, Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature, Cancer Treat Rev, 80, 101892, 10.1016/j.ctrv.2019.101892 Guckenberger, 2020, Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation, Lancet Oncol, 21, e18, 10.1016/S1470-2045(19)30718-1 Lievens, 2020, Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document, Radiother Oncol, 148, 157, 10.1016/j.radonc.2020.04.003 Gönen, 2005, Concordance probability and discriminatory power in proportional hazards regression, Biometrika, 92, 965, 10.1093/biomet/92.4.965 Tanadini-Lang, 2017, Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease, Radiother Oncol, 123, 182, 10.1016/j.radonc.2017.01.003 Benjamin, 2018, Redefine statistical significance, Nat Hum Behav, 2, 6, 10.1038/s41562-017-0189-z Chen, 2020, Prognostic significance of oligometastatic disease classification by the ESTRO/EORTC of cancer for patients with lung cancer treated with definitive radical radiotherapy, Anticancer Res, 40, 5895, 10.21873/anticanres.14609 Pembroke, 2018, Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression, Radiother Oncol, 127, 493, 10.1016/j.radonc.2018.04.022 Poon, 2020, Evaluation of definitive stereotactic body radiotherapy and outcomes in adults with extracranial oligometastasis, JAMA Netw Open, 3, e2026312, 10.1001/jamanetworkopen.2020.26312 Fleckenstein, 2016, Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer, BMC Cancer, 16, 348, 10.1186/s12885-016-2379-x Li, 2019, Prognostic factors and optimal response interval for stereotactic body radiotherapy in patients with lung oligometastases or oligoprogression from colorectal cancer, Front Oncol, 9, 10.3389/fonc.2019.01080 Prasad, 2011, Medical reversal: why we must raise the bar before adopting new technologies, Yale J Biol Med, 84, 471